8月21日 - ** 美国生物技术公司斯托克治疗公司（Stoke Therapeutics STOK.O）的股价在盘前交易中上涨1.4%，至31.85美元
** 摩根大通恢复该股覆盖，给予“增持”评级，目标价40美元
** 该行认为“zorevunersen治疗德拉维特综合征的III期EMPEROR试验在减少癫痫发作这一主要终点上成功概率极高”
** 本月早些时候，受合作及授权收入下降影响，STOK第二季度营收下滑，净亏损扩大
** 全部14家券商对STOK的评级均为“买入”或更高；目标价中位数为46美元——LSEG数据
** 截至上一交易日收盘，该股年内累计下跌1%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.